JP2022542448A5 - - Google Patents
Info
- Publication number
- JP2022542448A5 JP2022542448A5 JP2022506468A JP2022506468A JP2022542448A5 JP 2022542448 A5 JP2022542448 A5 JP 2022542448A5 JP 2022506468 A JP2022506468 A JP 2022506468A JP 2022506468 A JP2022506468 A JP 2022506468A JP 2022542448 A5 JP2022542448 A5 JP 2022542448A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- residue corresponding
- acid residue
- sequence
- hla class
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962880509P | 2019-07-30 | 2019-07-30 | |
| US62/880,509 | 2019-07-30 | ||
| US202063029115P | 2020-05-22 | 2020-05-22 | |
| US63/029,115 | 2020-05-22 | ||
| PCT/IB2020/057174 WO2021019474A1 (en) | 2019-07-30 | 2020-07-29 | Mhc class ii molecules and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022542448A JP2022542448A (ja) | 2022-10-03 |
| JP2022542448A5 true JP2022542448A5 (enExample) | 2023-08-08 |
| JP7811541B2 JP7811541B2 (ja) | 2026-02-05 |
Family
ID=74230294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506468A Active JP7811541B2 (ja) | 2019-07-30 | 2020-07-29 | Ｍｈｃクラスｉｉ分子及びその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220281949A1 (enExample) |
| EP (1) | EP4004033A4 (enExample) |
| JP (1) | JP7811541B2 (enExample) |
| KR (1) | KR20220052944A (enExample) |
| CN (1) | CN114502580B (enExample) |
| AU (1) | AU2020319732A1 (enExample) |
| BR (1) | BR112022001702A2 (enExample) |
| CA (1) | CA3146296A1 (enExample) |
| IL (1) | IL290231A (enExample) |
| MX (1) | MX2022001211A (enExample) |
| TW (1) | TW202118781A (enExample) |
| WO (1) | WO2021019474A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113795583B (zh) | 2019-03-04 | 2026-03-27 | 大学健康网络 | T细胞受体及其使用方法 |
| WO2021019473A1 (en) | 2019-07-30 | 2021-02-04 | University Health Network | Mhc class ii molecules and methods of use thereof |
| WO2021019475A1 (en) * | 2019-07-30 | 2021-02-04 | University Health Network | Mhc class ii molecules and methods of use thereof |
| CN118662607A (zh) * | 2023-03-15 | 2024-09-20 | 中国科学院上海巴斯德研究所 | 抑制过激炎性反应的蛋白及其应用 |
| WO2025050088A1 (en) * | 2023-08-31 | 2025-03-06 | Adaptive Biotechnologies Corporation | Agents and methods for preventing or inhibiting adaptive immune responses associated with multiple sclerosis |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005005631A1 (ja) * | 2003-07-11 | 2005-01-20 | Dainippon Sumitomo Pharma Co., Ltd. | リビン由来のｈｌａ-ａ２４結合性癌抗原ペプチド |
| US20060228758A1 (en) | 2004-09-13 | 2006-10-12 | Xencor, Inc. | Analysis of MHC-peptide binding interactions |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| JP6498600B2 (ja) * | 2012-06-08 | 2019-04-10 | ストロ バイオファーマ インコーポレーテッド | 部位特異的な非天然アミノ酸残基を含む抗体、その調製方法、及びその使用方法 |
| US9717758B2 (en) * | 2013-05-17 | 2017-08-01 | University Of Massachusetts | High-affinity DMF5 T cell receptor (TCR) variants |
| WO2016135363A1 (es) | 2015-02-23 | 2016-09-01 | Servicio Andaluz De Salud | Método de obtención de datos útiles para predecir o pronosticar la transmisión vertical, la cronificación y/o el aclaramiento del virus de la hepatitis c |
| CN108884140B (zh) * | 2015-12-03 | 2022-10-25 | 朱诺治疗学股份有限公司 | 修饰的嵌合受体及相关组合物和方法 |
| WO2017106684A2 (en) * | 2015-12-17 | 2017-06-22 | Janssen Biotech, Inc. | Antibodies specifically binding hla-dr and their uses |
| GB201604492D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
| WO2020028627A1 (en) * | 2018-08-01 | 2020-02-06 | Regents Of The University Of Minnesota | Co-receptor affinity enhanced major histocompatibility class ii molecules |
-
2020
- 2020-07-29 WO PCT/IB2020/057174 patent/WO2021019474A1/en not_active Ceased
- 2020-07-29 EP EP20847581.4A patent/EP4004033A4/en active Pending
- 2020-07-29 CA CA3146296A patent/CA3146296A1/en active Pending
- 2020-07-29 AU AU2020319732A patent/AU2020319732A1/en active Pending
- 2020-07-29 CN CN202080068318.7A patent/CN114502580B/zh active Active
- 2020-07-29 US US17/631,824 patent/US20220281949A1/en active Pending
- 2020-07-29 MX MX2022001211A patent/MX2022001211A/es unknown
- 2020-07-29 JP JP2022506468A patent/JP7811541B2/ja active Active
- 2020-07-29 TW TW109125667A patent/TW202118781A/zh unknown
- 2020-07-29 BR BR112022001702A patent/BR112022001702A2/pt unknown
- 2020-07-29 KR KR1020227006945A patent/KR20220052944A/ko active Pending
-
2022
- 2022-01-30 IL IL290231A patent/IL290231A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI835730B (zh) | Ｔｃｒ及肽 | |
| Bachem et al. | Superior antigen cross-presentation and XCR1 expression define human CD11c+ CD141+ cells as homologues of mouse CD8+ dendritic cells | |
| AU2018231405B2 (en) | MR1 restricted T cell receptors for cancer immunotherapy | |
| CN114502580B (zh) | Mhc ii类分子及其使用方法 | |
| WO2016184592A1 (en) | T cell receptor with specificity for myeloperoxidase peptide and uses thereof | |
| US11702459B2 (en) | MR1 restricted T cell receptors for cancer immunotherapy | |
| Zhang et al. | The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8+ T cell exhaustion | |
| CN111032686A (zh) | 血液恶性肿瘤的治疗 | |
| JP2022542447A5 (enExample) | ||
| CA3115022A1 (en) | Specific t cell receptors against epitopes of mutant myd88l265p protein for adoptive t cell therapy | |
| JP2022542445A5 (enExample) | ||
| JP7811540B2 (ja) | Ｍｈｃクラスｉｉ分子及びその使用方法 | |
| WO2019126799A1 (en) | Major histocompatibility complex (mhc) compositions and methods of use thereof | |
| IT202000006973A1 (it) | Antigeni herv tumore-specifici e loro uso nella immunoterapia del cancro | |
| Kim et al. | In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells | |
| JP2022527322A5 (enExample) | ||
| CN114450303B (zh) | Mhc ii类分子及其使用方法 | |
| EP4735471A2 (en) | T-cell receptors | |
| EP4731758A2 (en) | Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy | |
| JP2024505111A (ja) | 改善された抗がん活性を有するｔ細胞の選択方法 | |
| Watanabe et al. | Establishment of a stable T lymphoma cell line transduced with HLA-A∗ 24: 02-restricted WT1-specific TCR genes and its application to antigen-specific immunomonitoring | |
| EP4491630A1 (en) | T-cell receptor for acute myeloid leukemia (aml) | |
| US20210115137A1 (en) | Prophylactic or therapeutic agent for tumors, pd-l1 inhibitor, screening method for prophylactic or therapeutic agent for tumors, and screening method for pd-l1 inhibitor | |
| Carr | Mechanisms of NK cell recognition of HCMV infected cells | |
| JP2022191531A (ja) | Ｕｒｌｃ１０由来ペプチドまたはｄｅｐｄｃ１由来ペプチドを認識するヒトｔ細胞が発現するｔ細胞受容体 |